Put companies on watchlist
Cannovum AG
ISIN: DE000A2LQU21
WKN: A2LQU2
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cannovum AG · ISIN: DE000A2LQU21 · EQS - Company News (50 News)
Country: Germany · Primary market: Germany · EQS NID: 1265314
06 January 2022 08:40AM

Cannovum AG now offers Next Day Delivery for med. cannabis


DGAP-News: Cannovum AG / Key word(s): Miscellaneous
Cannovum AG now offers Next Day Delivery for med. cannabis

06.01.2022 / 08:40
The issuer is solely responsible for the content of this announcement.


Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) shortens the Germany-wide delivery times for its cannabis products. From now on, delivery to every pharmacy throughout Germany will take place directly on the next working day if the order is placed by 12:30 pm.

The new logistics structures have been extensively tested and the pilot phase has been successfully completed with positive results. With this process optimization, Cannovum is also preparing for the upcoming requirements of the legalization of cannabis as a stimulant, which will require secure and reliable logistics on a completely different scale than before.

"Fast and reliable delivery times of narcotics are crucial for pharmacies. It is important to us to continuously improve the supply of cannabis-based medications to patients. Furthermore, optimizing our logistics processes is another step towards becoming a reliable partner for licensed cannabis specialty stores," says Pia Marten, CEO of Cannovum AG.

Contact:

Linda Rasch, IR & PR, Cannovum AG
Phone +49 30 3982 163 62, linda.rasch@cannovum.com


Cannovum AG is the first German listed medical cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit www.cannovum.com



06.01.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Cannovum AG
Rheinsberger Str. 76/77
10115 Berlin
Germany
Phone: +49 (0)30 3982 16360
E-mail: ir@cannovum.com
Internet: www.cannovum.com
ISIN: DE000A2LQU21
WKN: A2LQU2
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich
EQS News ID: 1265314

 
End of News DGAP News Service

1265314  06.01.2022 

fncls.ssp?fn=show_t_gif&application_id=1265314&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.